AstraZeneca says its COVID-19 vaccine is 79 percent effective in large U.S. trial


AstraZeneca and Oxford University said Monday that their COVID-19 vaccine proved to be 79 percent effective against symptomatic illness and 100 percent effective at preventing serious COVID-19 cases or hospitalization in a U.S. trial involving more than 30,000 people. The vaccine, tested on 32,559 people 18 and older was effective among all age groups and demographics, including 80 percent effective with participants 65 and older.
The U.S. trial's independent safety monitors, aided by an outside neurologist, specifically reviewed the trail data for increased risk of severe blood clotting, following reports of vaccinated people in Europe suffering from cerebral venous sinus thrombosis. The review found no increased risk of thrombosis in the 21,583 volunteers who received at least one dose of the vaccine; the other participants were given a placebo.
A YouGov poll published Monday found that a growing number of adults in Spain, Germany, France, and Italy believe the AstraZeneca vaccine is unsafe, following a brief suspension of the vaccine in those countries last week. They began using the vaccine again after the European Medicines Agency and World Health Organization affirmed that AstraZeneca's vaccine is safe and effective.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Public confidence in this vaccine, developed by Oxford researchers, is especially important for the global vaccination effort. The vaccine is already the most-used shot in many countries, and largely because of its price — about $4 a dose — and ability to be stored in a normal refrigerator, it is central to the efforts to vaccinate the developing world.
The U.S. has also ordered 300 million doses, though the Food and Drug Administration has not yet given it emergency use authorization. AstraZeneca said Monday it will submit the full results of its U.S. trial to the FDA and for peer review to be published in a journal.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Nashville dining: Far more than barbecue and hot chicken
Feature A modern approach to fine-dining, a daily-changing menu, and more
-
Music Reviews: Coco Jones and Viagra Boys
Feature "Why Not More?" and "Viagr Aboys"
-
Visa wants to let AI make credit card purchases for you
The Explainer The program will allow you to set a budget and let AI learn from your shopping preferences
-
Warren Buffet announces surprise retirement
speed read At the annual meeting of Berkshire Hathaway, the billionaire investor named Vice Chairman Greg Abel his replacement
-
Trump calls Amazon's Bezos over tariff display
Speed Read The president was not happy with reports that Amazon would list the added cost from tariffs alongside product prices
-
Markets notch worst quarter in years as new tariffs loom
Speed Read The S&P 500 is on track for its worst month since 2022 as investors brace for Trump's tariffs
-
Tesla Cybertrucks recalled over dislodging panels
Speed Read Almost every Cybertruck in the US has been recalled over a stainless steel panel that could fall off
-
Crafting emporium Joann is going out of business
Speed Read The 82-year-old fabric and crafts store will be closing all 800 of its stores
-
Trump's China tariffs start after Canada, Mexico pauses
Speed Read The president paused his tariffs on America's closest neighbors after speaking to their leaders, but his import tax on Chinese goods has taken effect
-
Chinese AI chatbot's rise slams US tech stocks
Speed Read The sudden popularity of a new AI chatbot from Chinese startup DeepSeek has sent U.S. tech stocks tumbling
-
US port strike averted with tentative labor deal
Speed Read The strike could have shut down major ports from Texas to Maine